Pharmacology
9 questionsWhich of the following statements represents the most clinically significant aspect of drug metabolism?
Which of the following is an example of topical administration producing only local effects (not systemic)?
Maximum effect of bronchodilatation in asthma is caused by -
What is an atypical side effect of montelukast?
Which of the following statements about oral iron preparations is correct?
Which of the following statements best describes the underlying mechanism of heparin-induced thrombocytopenia?
What is the mechanism of action of ticagrelor?
Which of the following medications is classified as a stool softener?
What is the drug of choice for drug-induced peptic ulcer?
NEET-PG 2015 - Pharmacology NEET-PG Practice Questions and MCQs
Question 451: Which of the following statements represents the most clinically significant aspect of drug metabolism?
- A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
- B. Glucuronidation is a phase II reaction
- C. Reduction is a phase I reaction
- D. Cytochrome P450 is involved in phase I reactions
Explanation: ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.
Question 452: Which of the following is an example of topical administration producing only local effects (not systemic)?
- A. Topical corticosteroid cream (Correct Answer)
- B. Sublingual nitroglycerin
- C. Transdermal patch
- D. Rectal diazepam
Explanation: ***Topical corticosteroid cream*** - When applied to the skin for conditions like dermatitis, topical corticosteroids primarily exert their effects at the site of application, reducing **local inflammation** and itching. - While systemic absorption can occur with potent steroids over large areas, typical use aims for **localized action** without significant systemic effects. *Sublingual nitroglycerin* - This route is designed for **rapid systemic absorption** through the oral mucosa, bypassing first-pass metabolism to quickly treat angina. - The goal is a **widespread vasodilatory effect** throughout the body, not a local one within the mouth. *Transdermal patch* - Transdermal patches, such as those for nicotine or fentanyl, are specifically designed to deliver medication **systemically** through the skin into the bloodstream over a prolonged period. - They provide a **sustained release** and systemic therapeutic effect throughout the body. *Rectal diazepam* - Administered rectally, diazepam is absorbed into the systemic circulation to produce **CNS effects** such as sedation, anxiolysis, or anticonvulsant activity. - Although the administration is local, the intended clinical effect is **systemic** and widespread throughout the body.
Question 453: Maximum effect of bronchodilatation in asthma is caused by -
- A. Beta 2-Agonist (Correct Answer)
- B. Corticosteroids
- C. Theophylline
- D. Anticholinergic
Explanation: ***Beta 2-Agonist*** - **Beta-2 agonists** directly relax bronchial smooth muscle by stimulating beta-2 adrenergic receptors, leading to significant and rapid bronchodilation. - This direct action on airway muscle relaxation makes them the most potent and fastest-acting bronchodilators for acute asthma symptoms. *Corticosteroids* - **Corticosteroids** reduce airway inflammation and hypersensitivity over time but do not provide immediate or maximal bronchodilation. - Their primary role is in long-term control of asthma, preventing exacerbations rather than acutely reversing bronchospasm. *Theophylline* - **Theophylline** is a methylxanthine that causes modest bronchodilation by inhibiting phosphodiesterase and blocking adenosine receptors. - It has a narrow therapeutic index, numerous side effects, and is less effective than beta-2 agonists for bronchodilation. *Anticholinergic* - **Anticholinergics** (e.g., ipratropium) block muscarinic receptors, preventing acetylcholine-induced bronchoconstriction. - They provide bronchodilation but are generally less potent and have a slower onset of action compared to beta-2 agonists in asthma.
Question 454: What is an atypical side effect of montelukast?
- A. Goodpasture syndrome
- B. Membranous glomerulonephritis
- C. Bronchial asthma
- D. Churg-Strauss syndrome (Correct Answer)
Explanation: ***Churg-Strauss syndrome*** - The apparent development of **Churg-Strauss syndrome** (eosinophilic granulomatosis with polyangiitis) has been reported in patients treated with montelukast, although it is believed to be related more to the unmasking of the disease rather than a direct drug effect. - This typically occurs when **corticosteroids** are tapered or withdrawn as montelukast takes over, revealing the underlying vasculitis. *Goodpasture syndrome* - **Goodpasture syndrome** is an autoimmune disease causing rapidly progressive glomerulonephritis and pulmonary hemorrhage, characterized by anti-glomerular basement membrane (GBM) antibodies. - There is no established association between montelukast use and the development of Goodpasture syndrome. *Membranous glomerulonephritis* - **Membranous glomerulonephritis** is a common cause of nephrotic syndrome, characterized by immune complex deposition on the glomerular basement membrane. - This condition is not typically linked to the use of montelukast. *Bronchial asthma* - **Bronchial asthma** is the condition montelukast is used to treat, acting as a leukotriene receptor antagonist to reduce inflammation and bronchoconstriction. - It is a primary indication for the drug, not a side effect.
Question 455: Which of the following statements about oral iron preparations is correct?
- A. Most commonly used preparation is ferrous gluconate
- B. Ferrous fumarate is most efficient
- C. Ferric preparations are more effective
- D. Different preparations have different bioavailability (Correct Answer)
Explanation: ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.
Question 456: Which of the following statements best describes the underlying mechanism of heparin-induced thrombocytopenia?
- A. Low molecular weight heparin can also cause heparin-induced thrombocytopenia.
- B. Vitamin K is not an antidote for heparin-induced thrombocytopenia.
- C. Heparin-induced thrombocytopenia can occur after several days of heparin therapy.
- D. Antibodies are formed against heparin-platelet factor 4 complexes. (Correct Answer)
Explanation: **_Antibodies are formed against platelet factor 4._** - The underlying mechanism of **heparin-induced thrombocytopenia (HIT)** involves the formation of antibodies against complexes of **heparin and platelet factor 4 (PF4)** [2]. - These antibodies bind to the **heparin-PF4 complexes** on the surface of platelets, leading to platelet activation, aggregation, and consumption, which results in thrombocytopenia and a prothrombotic state [2]. *Low molecular weight heparin can also cause heparin-induced thrombocytopenia.* - While **low molecular weight heparin (LMWH)** has a lower incidence of causing HIT compared to unfractionated heparin, it can still trigger the condition [1], [2]. - This is because LMWH, like unfractionated heparin, can form complexes with PF4, leading to the same immune response in susceptible individuals [2]. *Vitamin K is not an antidote for heparin-induced thrombocytopenia.* - **Vitamin K** is the antidote for warfarin overdose, which works by reversing its anticoagulant effects [3]. - It has no role as an antidote for HIT because HIT is an **immune-mediated reaction** involving platelet activation, not a direct anticoagulant effect that can be reversed by Vitamin K [2]. *Heparin-induced thrombocytopenia can occur after several days of heparin therapy.* - HIT typically manifests after **5 to 10 days of heparin exposure**, as it takes time for the immune system to produce antibodies against the heparin-PF4 complexes [2]. - However, in patients with prior exposure to heparin, HIT can occur much sooner, even within **24 hours**, due to pre-existing antibodies.
Question 457: What is the mechanism of action of ticagrelor?
- A. Reversible inhibition of ADP action (Correct Answer)
- B. Irreversible inhibition of ADP action
- C. Reversible inhibition of GPIIb/IIIa
- D. Irreversible inhibition of GPIIb/IIIa
Explanation: ***Reversible inhibition of ADP action*** - **Ticagrelor** is a **P2Y12 receptor antagonist** that works by preventing ADP from binding to its receptor on platelets [2]. - This binding is **reversible**, meaning ticagrelor can dissociate from the receptor, allowing for some recovery of platelet function over time [2]. *Irreversible inhibition of ADP action* - **Clopidogrel** and **prasugrel** are examples of **irreversible P2Y12 inhibitors**, forming a permanent bond with the receptor [2]. - Irreversible inhibition leads to a longer duration of platelet inhibition, as new platelets must be generated for function to return [2]. *Reversible inhibition of GPIIb/IIIa* - **GPIIb/IIIa inhibitors** like **eptifibatide** and **tirofiban** block the final common pathway of platelet aggregation by preventing fibrinogen binding [1]. - While their action is reversible, they target a *different* mechanism than ticagrelor. *Irreversible inhibition of GPIIb/IIIa* - **Abciximab** is a GPIIb/IIIa inhibitor that binds **irreversibly** (or with very slow dissociation) to the receptor [1]. - Unlike reversible GPIIb/IIIa inhibitors, abciximab is a monoclonal antibody with a prolonged antiplatelet effect [1]. - This is still an incorrect answer as ticagrelor targets the P2Y12 receptor, not GPIIb/IIIa.
Question 458: Which of the following medications is classified as a stool softener?
- A. Bran
- B. Senna
- C. Phenolphthalein
- D. Docusates (Correct Answer)
Explanation: **Docusates** - **Docusates** (e.g., docusate sodium, docusate calcium) are **stool softeners** that work by reducing the surface tension of stool, allowing water and lipids to penetrate. - This increases the water content in the stool, making it softer and easier to pass, which is particularly useful in preventing straining after surgery or in conditions like hemorrhoids. *Bran* - **Bran** is a **bulk-forming laxative**, a type of dietary fiber that adds mass to the stool. - It absorbs water in the intestines, which increases stool volume and stimulates bowel movements, but it does not directly soften the stool in the same way docusates do. *Senna* - **Senna** is a **stimulant laxative** that works by irritating the bowel wall to promote peristalsis and bowel evacuation. - While it can help move stool, it does not act primarily by softening it, and prolonged use can lead to dependency or electrolyte imbalances. *Phenolphthalein* - **Phenolphthalein** is a **stimulant laxative** that was historically used to promote bowel movements. - It is no longer widely used due to concerns about potential carcinogenicity and other adverse effects, and it does not function as a stool softener.
Question 459: What is the drug of choice for drug-induced peptic ulcer?
- A. Prostaglandin analogues
- B. H2-receptor antagonists
- C. Proton pump inhibitors (Correct Answer)
- D. Antacids
Explanation: ***Proton pump inhibitors*** - **PPIs** are the most effective agents for treating and preventing **NSAID-induced peptic ulcers** by profoundly suppressing gastric acid secretion. - They provide **rapid symptom relief** and promote ulcer healing by creating an environment conducive to mucosal repair. *Prostaglandin analogues* - **Misoprostol**, a prostaglandin E1 analogue, can prevent NSAID-induced ulcers, but its use is limited by **gastrointestinal side effects** such as diarrhea and abdominal cramping. - While they protect the gastric mucosa, their efficacy in healing established ulcers is generally **inferior to PPIs**. *H2-receptor antagonists* - **H2-blockers** are effective in reducing gastric acid, but they are **less potent** than PPIs and typically do not heal **gastric ulcers** as effectively, especially those induced by NSAIDs. - They are more commonly used for preventing **duodenal ulcers** and managing symptoms of GERD. *Antacids* - Antacids provide **immediate, temporary relief** of ulcer symptoms by neutralizing existing stomach acid. - They do not address the underlying pathology or promote **ulcer healing** and are therefore not considered the drug of choice for treatment.
Physiology
1 questionsRebound increase in gastric acid secretion after stopping proton pump inhibitor therapy is due to?
NEET-PG 2015 - Physiology NEET-PG Practice Questions and MCQs
Question 451: Rebound increase in gastric acid secretion after stopping proton pump inhibitor therapy is due to?
- A. Parietal cell hyperplasia
- B. Increased histamine release
- C. Hypergastrinemia (Correct Answer)
- D. Hypersensitivity of Ach receptors
Explanation: ***Hypergastrinemia*** - Proton pump inhibitors (PPIs) create a state of **hypochlorhydria** (reduced stomach acid), which in turn stimulates the **G cells** in the stomach to produce more **gastrin**. - This elevated gastrin level leads to a compensatory increase in the number and activity of **parietal cells**, causing a rebound hypersecretion of acid when PPI therapy is discontinued. *Parietal cell hyperplasia* - While parietal cell hyperplasia can occur, it is a consequence of chronic **hypergastrinemia**, not the primary driver of rebound acid secretion. - The direct effect of increased gastrin stimulating existing parietal cells is more immediate and significant for the rebound phenomenon. *Increased histamine release* - Elevated histamine release from **enterochromaffin-like (ECL) cells** is a downstream effect of hypergastrinemia, as gastrin stimulates ECL cells. - While increased histamine contributes to acid secretion, the root cause for its increase in this context is the **hypergastrinemia** induced by PPIs. *Hypersensitivity of Ach receptors* - **Acetylcholine (Ach) receptors** on parietal cells are involved in direct neural stimulation of acid secretion. - There is no evidence that stopping PPIs causes an increased sensitivity of these receptors, or that this is the primary mechanism of rebound acid secretion.